Spirogen regains rights to Phase II anticancer from Ipsen
This article was originally published in Scrip
Executive Summary
Spirogen, a UK developer of DNA-interactive drugs, has regained control of SJG-136(now known as SG2000) from its licensing partner Ipsen.